Compare Regeneron Pharmaceuticals Inc (REGN) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Materials Select Sector SPDR Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B), while Materials Select Sector SPDR Fund trades at $49.23 (market cap $7.73B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 9.8× Materials Select Sector SPDR Fund's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| REGN | XLB | |
|---|---|---|
Market Cap | $76.14B | $7.73B |
Volume | 500,239 | 13,681,146 |
Sector | Health | — |
52-Week High | $852.03 | $53.67 |
52-Week Low | $557.73 | $42.23 |
Typical Hold Time | 107 Days | 70 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
XLB, the Materials Select Sector SPDR ETF, trades at $48.98, down 1.51% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX signaling strong selling pressure. The ETF's portfolio is heavily concentrated in chemicals (49% of assets), and recent news highlights sector volatility amid broader market challenges outside of tech. A dividend of $0.23 is scheduled for September 2026, but financial ratios are currently unavailable.
The outlook for XLB is cautious due to technical weakness and sector cyclicality, though long-term infrastructure and AI-related demand offer potential upside. Risks include economic sensitivity and high concentration, while investor sentiment remains mixed with some analysts seeing value in materials as an AI-resistant play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
